NEW YORK, Dec 31, 2025, 1:25 ET
- Lupin said its VISUfarma acquisition is now expected to close by Feb. 28, 2026, extending its earlier end-2025 timeline.
- Separately, Lupin signed an exclusive India licensing and supply deal with China’s Gan & Lee for bofanglutide, a fortnightly GLP-1 diabetes and weight-loss injection.
- The moves underscore Lupin’s push to expand in specialty ophthalmology and tap fast-growing demand for obesity and diabetes medicines.
Lupin said the closing timeline for its acquisition of Dutch eye-care company VISUfarma has been extended, with the transaction now expected to be completed by Feb. 28, 2026.
The delay matters because Lupin has pitched VISUfarma as a pillar of its specialty strategy in Europe, and the revised date pushes the deal past the company’s earlier goal of closing by the end of 2025.
Lupin said the VISUfarma transaction is progressing and remains subject to customary closing conditions.
VISUfarma, based in the Netherlands, would be acquired through Lupin’s wholly owned subsidiary Nanomi, Lupin has said.
Lupin announced the VISUfarma deal in late September, saying it would strengthen its global specialty ophthalmology business and broaden its portfolio in areas such as dry eye and glaucoma.
The company also said at the time that it planned to finance the acquisition using existing cash on its balance sheet.
In a separate development this week, Lupin said it struck an exclusive license, supply and distribution agreement with China-based Gan & Lee Pharmaceuticals for bofanglutide, a novel GLP-1 receptor agonist designed for once-every-two-weeks dosing.
GLP-1 medicines mimic a gut hormone that helps regulate blood sugar and appetite, and have become a major battleground for drugmakers targeting diabetes and obesity.
Under the agreement, Lupin will have exclusive rights to commercialize and distribute bofanglutide in India, it said.
“We are committed to offering the best solutions for managing chronic metabolic diseases like Diabetes,” Lupin Managing Director Nilesh Gupta said in a statement. MarketScreener
The Gan & Lee pact adds to Lupin’s efforts to expand beyond its core generics franchise into specialty products and higher-growth therapeutic areas.
